Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Pet3.2
Petrelintide – Forschung
Überwiegend Mechanismus / Beobachtung
5 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Petrelintide sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen randomisierten Studien, veröffentlicht 2021–2026 mit einer typischen Studiengröße von 706 Teilnehmenden.
Basierend auf 5 Studien · 2 RCTs · 706 Teilnehmende insgesamt
Konfidenz
Geringe Konfidenz
Nach Outcome
Weight loss & obesityIn einer Phase-1-Studie mit multiplen aufsteigenden Dosen reduzierte Petrelintid das Körpergewicht nach 16 Wochen um bis zu ~8,6 % bei Erwachsenen mit Übergewicht/Adipositas, bei guter Verträglichkeit · Über ~16 Wochen
Überwiegend Mechanismus / Beobachtung5 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung3 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung3 Studien
Aktives Forschungsgebiet
5 Studien in den letzten 5 Jahren
20212026
1RCTn=706 · large study2021
Mean percentage weight reductions from baseline were greater with all doses of cagrilintide (0·3-4·5 mg, 6·0%-10·8%) versus placebo (3·0%)... Weight reductions were also greater with cagrilintide 4·5 mg versus liraglutide 3·0 mg (10·8% vs 9·0%).
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. · Lancet (2021)
Phase-2, double-blind, randomised, placebo- and active-controlled dose-finding trial across 57 sites in ten countries; 706 adults with overweight/obesity (no diabetes) on once-weekly subcutaneous cagrilintide 0.3-4.5 mg vs liraglutide 3.0 mg vs placebo over 26 weeks
Mean weight loss ranged 6.0-10.8% across cagrilintide doses vs 3.0% placebo; the 4.5 mg dose modestly beat liraglutide 3 mg (10.8% vs 9.0%)
Gastrointestinal disorders (nausea, constipation, diarrhoea) and administration-site reactions were the most frequent adverse events; GI events 41-63% across doses vs 32% placebo
Petrelintide was slowly absorbed, had a half-life of ~10 days, showed steady-state dose proportionality, and reduced body weight by up to 8.6% after 16 weeks... appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss.
Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T. · Diabetes Obes Metab (2026)
Petrelintide-specific. The pivotal early human dataset: two randomised, placebo-controlled, double-blind phase-1 trials (single ascending dose 0.04-2.4 mg SC plus a 0.35 mg IV dose; and multiple-ascending-dose once-weekly SC escalated to 2.4/4.8/9.0 mg) in normal/overweight adults and adults with overweight/obesity
Well tolerated with no serious or severe treatment-emergent adverse events; nausea was the most common GI event (16.7-33.3% petrelintide vs 16.7% placebo in MAD part 2), diarrhoea rare and vomiting only in the one participant who discontinued
Slowly absorbed with a ~10-day half-life (supporting once-weekly dosing) and steady-state dose proportionality; reduced body weight by up to ~8.6% after 16 weeks
Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234.
Bailey CJ, Flatt PR, Conlon JM. · Peptides (2026)
Amylin-class context, NOT petrelintide-specific outcome data. Review of long-acting amylin-related peptides for obesity and type 2 diabetes, covering pramlintide, cagrilintide/CagriSema, amycretin, and petrelintide
Names petrelintide among recently developed long-acting amylin analogues 'shown strong efficacy as monotherapy in clinical trials' — but the detailed evidence summarised is for the broader class
Describes the established amylin mechanism: central satiety induction, slowed gastric emptying, suppressed prandial glucagon; GI side effects (especially nausea) common during initiation and up-titration but mostly resolving
Herein, we report the development of petrelintide, a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH... Petrelintide is in clinical development as a potential treatment for weight management.
Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L. · J Med Chem (2025)
Petrelintide-specific. Medicinal-chemistry discovery/development paper (Zealand Pharma with Boehringer Ingelheim) describing the design of petrelintide to overcome amylin's amyloid aggregation and short half-life
Engineered for chemical stability while retaining in vitro and in vivo potency, and formulable at near-neutral pH to enable potential co-formulation with other weight-management peptides
Establishes petrelintide as a stable long-acting human amylin analogue selected for clinical development in obesity
The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists... including pramlintide and cagrilintide... and investigational drugs, including ZP8396 and amycretin.
Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S, Pal A, Arora V. · Vascul Pharmacol (2026)
Amylin-class context, NOT petrelintide-specific outcome data. Review of amylin-receptor agonists for obesity, including pramlintide, cagrilintide, KBP-series DACRAs, and investigational agents including ZP8396 (petrelintide) and amycretin
Details amylin-receptor (calcitonin-receptor + RAMP) molecular biology and central homeostatic/hedonic feeding control — the mechanistic foundation for the class
Frames ZP8396/petrelintide as an investigational agent within an emerging class with enhanced pharmacokinetics and GLP-1 synergy potential